浙江诚意药业股份有限公司关于帕拉米韦注射液获得药品注册证书的公告

Overview - Zhejiang Chengyi Pharmaceutical Co., Ltd. has received the drug registration certificate for Palivizumab injection from the National Medical Products Administration [1] - The approval indicates that the product meets the requirements for drug registration according to the Drug Administration Law of the People's Republic of China [1] Drug Development and Related Information - Palivizumab injection is indicated for the treatment of influenza A or B [2] - The registration application was formally accepted on March 4, 2024, with a total R&D investment of 6.6968 million yuan (approximately 0.67 million) as of the announcement date [2] Market Situation - As of the announcement date, there are 35 manufacturers of Palivizumab injection, including Chengyi Pharmaceutical [2] - The product was selected in the 10th batch of national centralized procurement in December 2024, with nine winning companies [2] - The specified procurement volume for Palivizumab injection is 249,600 units for the 15ml:0.15g specification, 4,000 units for the 20ml:0.2g specification, and 53,500 units for the 60ml:0.3g specification [3] - The estimated market sales for Palivizumab injection in public medical institutions in 2024 is approximately 9.5 million yuan (0.95 million) [3]